Israeli company Galmed gets positive trial results for liver drug

TEL AVIV (Reuters) - Galmed Pharmaceuticals said on Tuesday patients in a mid-stage trial for its treatment for NASH, a fatty liver disease linked to obesity, showed a statistically significant reduction in liver fat.